Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-06-12
2011-12-20
Boesen, Agnieszka (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S091500, C436S811000, C436S501000
Reexamination Certificate
active
08080382
ABSTRACT:
This invention relates to the diagnosis and/or monitoring of patients with inflammatory diseases or conditions, e.g., immunologic, hematologic, vascular, or infectious diseases or conditions, by determining levels of complement pathway components on erythrocytes. Methods of diagnosing vascular diseases or conditions by determining levels of complement pathway components on platelets are also disclosed.
REFERENCES:
patent: 2005/0037441 (2005-02-01), Ahearn et al.
patent: WO 94/10571 (1994-05-01), None
patent: WO 03/022223 (2003-03-01), None
patent: WO 2004/093647 (2004-11-01), None
Sturfelt, Scan. J. Rheumatol. 2002, vol. 31, p. 129-132.
Manzi et al. Lupus, 2004, vol. 13, p. 298-303.
Wolbink et al. J. Immunol. 1996, vol. 157, p. 473-479.
Bohmig et al. (Journal of American Society of Nephrology, 2001, vol. 12, p. 2482-2489).
Giles et al. (Clinical Experimental Immunology, 1991, vol. 84, p. 263-269).
Baldwin et al. (Transplantation 1999, vol. 68, p. 894-900) total of 9 pages of the document generated as a PDF from HTML format.
Stroncek (Transfusion Medicine, 2003, vol. Feb. 2003, vol. 13, p. 35-41 in IDS of Feb. 20, 2009).
Freysdottir et al. (Journal of Immunological Methods, 1991, vol. 142, p. 45-52) in IDS Sep. 16, 2005.
Baldwin et al. (Transplantation 1999, vol. 68, p. 894-900) of record on May 2, 2008.
Salerno et al.(Xenotransplantation 2002, vol. 9, p. 125-134).
Iversen et al. (Nephrology Dial Transplant 1993, vol. 8, p. 1211-1214).
Atkinson, J.P., et al., “Origin of the Fourth Component of Complement Related Chido and Rodgers Blood Group Antigens;” 1988; Compliment; vol. 5; pp. 65-76.
Bombardier, Claire, et al., “Derivation of the SLEDAI A Disease Activity Index for.Lupus Patients;” Arthritis Rheum, Jun. 1992, vol. 35; No. 6; pp. 630-640.
Buyon, J.P., et al., “Assessment of disease activity and impending flare in patients with systemic lupus erythematosus;” Arthritis Rheum, 1992, vol. 35, pp. 1028-1037.
Falk, R.J.., et al., “Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus;” N. Engl. J. Med., 1985, vol. 312, pp. 1594-1599.
Jouvin, Marie-Helene et al.; “Decreased Expression of C3b Receptor(CR1)on Erythrocytes of Patients with Systemic Lupus erythematosus Contrasts with Its Normal Expression in Other Systemic Diseases and Does Not Correlate with the Occurrence or Severity of SLE Nephritis;” Complement;1986, vol. 3, pp. 88-96.
Lach-Trifilieff, Estelle, et al., “Complement Receptor 1(CD35)on Human Reticulocytes: Normal Express in Systemic Lupus Erythematosus and HIV-Infected Patients;” The Journal Of Immunology, vol. 162, No. 12, Jun. 1999, pp. 7549-7554.
Liang, Matthew H., et al., “Reliability and Validity of Six Systems for the Clinical Assessment of Disease Activity in Systemic Lupus Erythematosus,” Arthritis Rheum, Sep. 1989, vol. 32; No. 9; pp. 1107-1118.
Manzi, Susan, et al.; “Measurement of Erythrocyte C4d and Complement Receptor 1 in Systemic Lupus Erythematosus;” Nov. 2004, Arthritis & Rheumatism, vol. 50, No. 11, pp. 3596-3604.
ACCN. No. 85046338 Medline. McCarthy, T., et al., “Intrauterine devices and pelvic inflammatory disease;” Australian and New Zealand Journal of Obstretics and Gynecology, May 1984, vol. 24, No. 2, pp. 106-110, Abstract.
McGeer, P.L. et al.; “Reactions of the Immune System in Chronic Degenerative Neurological Diseases;” The Canadian Journal of Neurological Sciences; 1991, vol. 18; pp. 376-379.
ACCN. No. 90367342 Medline. Meliconi, R., et al., “Complement activation products in idiopathic pulmonary fibrosis: relevance of fragment Ba to disease severity;” Clinical Immunology and Immunopathology, Oct. 1990, vol. 57, No. 1, pp. 64-73, Abstract.
Navratil, J.S., et al., “Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited;” Curr. Rheumatol. Rep., 2000, vol. 2, pp. 32-38.
Ricker, D.M., et al., “Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels;” The Lupus Nephritis Collaborative Study Group, Am. J. Kidney Dis., 1991, vol. 18, pp. 678-685.
Senaldi, G., et al., “Correlation of the activation of the fourth component of complement(C4)with disease activity in systemic lupus erythematosus;” Ann. Rheum. Dis., 1988, vol. 47, pp. 913-917.
Tausk, Francisco, et al., “The Expression of C3b Receptors in the Differentiation of Discoid Lupus Erythematosus and Systemic Lupus Erythematosus;” Arthritis and Rheumatism, Jun. 1990, vol. 33, No. 6, pp. 888-892.
Tilley, C.A., et al., “Localisation of Chido and Rodgers Determinants to the C4d Fragment of Human C4;” Nature; Dec. 14, 1978; vol. 276; pp. 713-715.
Tsuboi, Y. et al.; “Increased concentration of C4d complement protein in CSF in amyotrophic laterial sclerosis”; Neurosurgery and Psychiatry 1994, vol. 57, pp. 859-861.
Yamada, T., et al. “Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d;” Neuroscience Letters, 1990, vol. 112, pp. 161-166.
Alexander, EL., et al., “Serum complement activation in central nervous system disease in sjogren's syndrome,”The American Journal of Medicine, Oct. 1988, vol. 85, No. 4, abstract only.
Chudwin, D., et al., “Activation of the Alternative Complement Pathway by Red Blood Cells from Patients with Sickle Cell Disease,”Clinical Immunology and Immunopathology, May 1994, vol. 71, No. 2, pp. 199-202.
Corvetta, Angelo et al.; “Low Number of Complement C3b/C4b Receptors (CR1) on Erythrocytes from Patients with Essential Mixed Cryoglobulinemia, Systemic Lupas Erythematosus and Rheumatoid Arthritis: Relationship with Disease Activity, Anticardiolipin Antibodies, Complement Activation and Therapy”; 1981,J. Rheumatol., vol. 18, pp. 1021-1025.
Cosio, F.G., et al., “The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients,”Transplantation, Oct. 27, 1996, vol. 62, No. 8, abstract only.
Freysdottir, Jona et al.; “A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes”; 1991,Journal of Immunological Methods, vol. 142, pp. 45-52.
Lamprecht, P., et al., “Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis,”Annals of the Rheumatic Diseases, Apr. 2001, vol. 60, pp. 385-390.
Manzi, Susan et al.; “Sensitivity and Specificity of Plasma and Urine Complement Split Products as Indicators of Lupus Disease Activity”; 1996,Arthritis&Rheumatism, vol. 39, No. 7, pp. 1178-1188.
Manzi, Susan et al.; “New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus”; 2004,Lupus, vol. 13, pp. 1-6.
Ross, Gordon D. et al.; “Disease-Associated Loss of Erythrocyte Complement Receptors (CR1, C3b Receptors) in Patients with Systemic Lupus Erythematosus and other Diseases Involving Autoantibodies and/or Complement Activation”; 1985,Journal of Immunology, vol. 135, No. 3, pp. 2005-2014.
Sirois, M., et al., “An Enzyme-linked Immunosorbent Assay for the Detection of Complement Components on Red Blood Cells,”Am. Journ. Clin. Path., Jul. 1984, vol. 82, No. 1, pp. 67-73.
Chaplin H. Jr. et al: “Characterization of Red Blood Cells Strongly Coated In Vitro by C3 via the Alternative Pathway” Transfusion (Bethesda), vol. 20, No. 3, 1980, pp. 256-262.
Hong F. et al: “Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies” Transfusion (Bethesda), vol. 31, No. 7, 1991, pp. 642-647.
Kanto T. et al: “Low expression of erythrocyte complement receptor type 1 induces defective immune complex c
Ahearn Joseph M.
Manzi Susan M.
Boesen Agnieszka
Klarkquist Sparkman, LLP
University of Pittsburgh - Of the Commonwealth System of Higher
LandOfFree
Monitoring immunologic, hematologic and inflammatory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monitoring immunologic, hematologic and inflammatory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monitoring immunologic, hematologic and inflammatory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255138